{"id":18,"date":"2025-04-01T18:23:00","date_gmt":"2025-04-01T16:23:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=991d3c6cccd52523400babe7adfdbc02"},"modified":"2025-04-01T18:31:22","modified_gmt":"2025-04-01T16:31:22","slug":"activepures-advanced-photohydrolysis-technology-demonstrates-rapid-inactivation-of-sars-cov-2-rsv-and-monkeypox-virus-in-aerosolized-form","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=18","title":{"rendered":"ActivePure\u2019s Advanced Photohydrolysis Technology Demonstrates Rapid Inactivation of SARS-CoV-2, RSV, and Monkeypox Virus in Aerosolized Form"},"content":{"rendered":"

\nA New Study conducted in partnership with The University of Texas Medical Branch (UTMB) and Published in the American Journal of Infection Control (AJIC) Shows Significant Reduction of Airborne Pathogens<\/i>\n<\/p><\/a><\/a>

DALLAS--(BUSINESS WIRE)--A new brief report published in the American Journal of Infection Control (AJIC) demonstrates that ActivePure\u2019s Advanced Photohydrolysis (AP) Technology effectively and rapidly inactivates aerosolized SARS-CoV-2, respiratory syncytial virus (RSV), and monkeypox virus (MPXV). The study highlights AP\u2019s potential as a valuable tool for improving indoor air quality and infection control, particularly in high-risk settings.\n<\/p>

\nAbout the Study:\n<\/p>

\nThe study, which was designed and conducted by researchers at the University of Texas Medical Branch (UTMB), aerosolized viral suspensions of SARS-CoV-2, RSV, and MPXV in a controlled chamber. Two devices were used: an experimental device equipped with AP technology and a control device without the technology. Viral concentrations were measured before and after the devices were activated to determine the reduction efficacy.\n<\/p>

\nKey findings include:\n<\/p>